Veterinary orthopedic Medicine Market - Global Industry Size, Share, Trends, Opportunity and Forecast, Segmented By Product Type (Biologics, Viscosupplements, Pharmaceuticals), By Animal type (Canine, Feline, Equine, Cattle, Swine, Others), By Route of Administration (Oral, Parenteral, Topical), By End Use (Veterinary Hospitals and Clinics, Homecare Settings, Others), By Region & Competition, 2021-2031F

Forecast Period	2027-2031
Market Size (2025)	USD 4.23 Billion
CAGR (2026-2031)	7.91%
Fastest Growing Segment	Viscosupplements
Largest Market	North America
Market Size (2031)	USD 6.68 Billion

Market Overview

The Global Veterinary Orthopedic Medicine Market will grow from USD 4.23 Billion in 2025 to USD 6.68 Billion by 2031 at a 7.91% CAGR. Veterinary orthopedic medicine encompasses the pharmaceutical and surgical management of musculoskeletal disorders in animals, specifically addressing fractures, joint diseases, and ligament injuries to restore mobility and alleviate pain. The market is primarily propelled by the intensifying humanization of pets, where owners view companion animals as integral family members, thereby increasing their willingness to invest in restorative procedures. Additionally, the rising prevalence of obesity among aging pet populations significantly drives the demand for medical interventions to treat osteoarthritis and other degenerative joint conditions.

Despite these favorable growth factors, the substantial financial burden associated with advanced surgical procedures and post-operative rehabilitation presents a significant challenge that may impede market expansion. High costs often render specialized orthopedic care inaccessible for uninsured or budget-constrained pet owners. According to the American Pet Products Association, in 2024, dog owners reported spending an average of $458 annually specifically on surgical veterinary visits. This data highlights the economic barrier that limits the adoption of expensive orthopedic treatments and potentially restricts the overall addressable market.

Key Market Drivers

The rapid expansion of pet health insurance coverage acts as a primary catalyst for the Global Veterinary Orthopedic Medicine Market by mitigating the financial barriers associated with advanced surgical interventions. As orthopedic procedures such as tibial plateau leveling osteotomy (TPLO) and total hip replacements carry significant costs, the presence of insurance policies provides the necessary safety net for owners to authorize these treatments rather than opting for euthanasia or conservative management. According to the North American Pet Health Insurance Association, May 2024, in the '2024 State of the Industry Report', the total premium volume for pet insurance in North America reached $4.27 billion in 2023. This financial buffer allows veterinarians to recommend optimal, gold-standard repair solutions without immediate rejection based on affordability. Furthermore, according to the Association of British Insurers, in 2024, insurers paid out a record £1 billion in pet insurance claims during the previous year, highlighting the substantial capital flowing into veterinary service providers which supports the viability of specialized orthopedic centers.

A concurrent surge in disposable income and overall veterinary healthcare spending further solidifies the market trajectory, driving demand for high-quality musculoskeletal care. Pet owners are increasingly prioritizing the longevity and quality of life of their animals, leading to higher expenditures on specialized medical services and premium orthopedic implants. This economic willingness creates a favorable environment for the adoption of customized solutions and advanced biological therapies. According to the American Pet Products Association, March 2024, in the 'State of the Industry' release, total pet industry expenditures in the United States climbed to $147 billion in 2023. This influx of capital empowers veterinary facilities to invest in better instrumentation and diagnostic equipment, thereby enhancing their capacity to treat complex orthopedic conditions that were previously unaddressed, ultimately expanding the addressable market for medical devices and pharmaceuticals.

Download Free Sample Report

Key Market Challenges

The substantial financial burden associated with advanced surgical procedures and post-operative rehabilitation constitutes a primary restraint on the global veterinary orthopedic medicine market. High procedural costs create a significant economic barrier, often compelling pet owners to forego necessary surgical interventions in favor of less expensive, palliative management options. When faced with the choice between costly restorative surgery and conservative treatment, budget-constrained owners frequently decline specialized care. This economic hesitation directly reduces the volume of surgeries performed, thereby limiting the revenue potential for manufacturers of orthopedic implants and surgical instrumentation.

This challenge is intensified by the rapid escalation of veterinary medical expenses, which often outpace general inflation and widen the affordability gap. According to the Association of British Insurers, in 2024, the average cost of a pet insurance claim rose to £685, with complex orthopedic treatments for conditions such as elbow dysplasia reaching as high as £50,000. Such elevated figures illustrate the severe financial exposure faced by uninsured pet owners. Consequently, the addressable market for orthopedic solutions remains restricted to a smaller demographic of affluent or insured clients, effectively capping the industry’s broader expansion potential.

Key Market Trends

The widespread adoption of monoclonal antibody (mAb) therapies is fundamentally reshaping veterinary orthopedic pain management by offering a targeted, monthly alternative to daily non-steroidal anti-inflammatory drugs. Unlike traditional pharmaceuticals that often carry risks of renal or hepatic toxicity, these biological agents specifically inhibit nerve growth factor to alleviate osteoarthritis pain with a superior safety profile. This technical shift towards species-specific biologics is driving substantial industry revenue, as veterinarians increasingly prioritize these injectables for long-term chronic care over conventional oral medications. According to Zoetis, February 2025, in the '2024 Annual Report', the company generated total revenue of $9.3 billion, a performance the firm directly attributed to the exceptional global uptake of its osteoarthritis pain franchise for dogs and cats.

Concurrently, the market is witnessing the robust integration of regenerative medicine and biologics, moving treatment paradigms from palliative symptom control to structural tissue repair. Advancements in allogeneic stem cell therapies and platelet-rich plasma are enabling practitioners to address the root causes of degenerative joint diseases by stimulating cartilage regeneration and modulating inflammation. This trend is supported by significant capital inflows aimed at standardizing these "off-the-shelf" biological solutions for widespread clinical use, thereby overcoming previous barriers related to donor sourcing and processing. According to dvm360, July 2025, in the article 'Veterinary stem cell therapy advances toward FDA approval with $18M in funding', Gallant Therapeutics secured $18 million in Series B financing specifically to accelerate the commercialization of its ready-to-use mesenchymal stem cell products for feline and canine orthopedic conditions.

Segmental Insights

Viscosupplements represent the fastest-growing segment within the global veterinary orthopedic medicine market, primarily driven by the increasing prevalence of osteoarthritis in the aging companion animal population. Veterinary professionals are prioritizing these injectable therapies as effective, minimally invasive alternatives to surgical intervention for joint management. This expansion is further supported by favorable product approvals from regulatory entities, such as the U.S. Food and Drug Administration, which have facilitated the availability of effective hyaluronic acid formulations. Consequently, the rising demand for long-term pain management solutions continues to accelerate the adoption of viscosupplements in veterinary practice.

Regional Insights

North America holds the leading position in the global veterinary orthopedic medicine market due to its comprehensive animal healthcare infrastructure and high pet ownership rates. The region benefits from the presence of key industry players actively developing treatments for musculoskeletal conditions. Furthermore, the U.S. Food and Drug Administration’s Center for Veterinary Medicine provides a clear regulatory pathway for product approvals, fostering market stability. Increasing expenditure on veterinary services and broadening pet insurance coverage also allow practitioners to adopt effective orthopedic therapies for companion animals.

Recent Developments

• In October 2025, Zoetis Inc. received approval from Health Canada for Lenivia (izenivetmab injection), a new therapy designed to alleviate pain associated with osteoarthritis in dogs. This regulatory milestone established the product as the first long-acting monoclonal antibody capable of providing up to three months of pain relief with a single subcutaneous injection. The company's Executive Vice President of Research and Development highlighted that the therapy targets nerve growth factor to effectively manage pain and inflammation for an extended period. This approval expands the company's portfolio of canine osteoarthritis treatments, offering a longer-duration alternative to existing monthly options and aiming to improve the quality of life for canine patients.
• In November 2024, Auxein Medical unveiled a comprehensive range of advanced orthopedic and arthroscopy products at the MEDICA trade fair in Düsseldorf, targeting the global medical and veterinary markets. The newly launched portfolio included the AV-Wiselock Plating System, an Osteochondral Transfer System, and various bioabsorbable implants designed to address the growing demand for minimally invasive procedures. The company emphasized that these innovative solutions were developed to improve surgical outcomes through enhanced compatibility and reduced post-operative complications. This strategic product launch underscored the manufacturer's commitment to delivering state-of-the-art trauma and orthopedic solutions to the healthcare community, including veterinary applications.
• In October 2024, Can-Fite BioPharma Ltd. announced positive final results from a multicenter clinical trial evaluating Piclidenoson for the treatment of osteoarthritis in dogs. The study, conducted in collaboration with Vetbiolix, demonstrated that the novel small molecule drug possessed a favorable safety and efficacy profile, showing potential as a safe alternative to traditional non-steroidal anti-inflammatory drugs. The Vice President of Business Development at the company stated that the successful data offered an opportunity to accelerate the drug's path to market. This breakthrough research highlighted the potential for a new disease-modifying therapy to address chronic joint pain in veterinary patients.
• In July 2024, Movora, a subsidiary of the Vimian Group, entered into a strategic partnership with VerticalVet to enhance the availability of advanced orthopedic solutions in the United States. This collaboration provided VerticalVet’s network of over 1,300 member clinics with direct access to a broad portfolio of surgical and orthopedic products. Additionally, the agreement included a comprehensive continuing education program aimed at training veterinarians and support staff in the latest orthopedic techniques. The Chief Executive Officer of Movora noted that this alliance aligned with their mission to advance veterinary surgery and expand the reach of their specialized medical technologies.

Key Market Players

• Enso Discoveries, LLC
• Zoetis, Inc.
• Boehringer Ingelheim International GmbH
• Elanco Animal Health Inc
• Biogenesis Bago SA
• American Regent, Inc..
• Merck & Co., Inc.
• Vetoquinol S.A.
• Ceva Santé Animale
• Virbac S.A.

By Product Type	By Animal type	By Route of Administration	By End Use	By Region
Biologics Viscosupplements Pharmaceuticals	Canine Feline Equine Cattle Swine Others	Oral Parenteral Topical	Veterinary Hospitals and Clinics Homecare Settings Others	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Veterinary Orthopedic Medicine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Orthopedic Medicine Market, By Product Type:

• Biologics
• Viscosupplements
• Pharmaceuticals

• Veterinary Orthopedic Medicine Market, By Animal type:

• Canine
• Feline
• Equine
• Cattle
• Swine
• Others

• Veterinary Orthopedic Medicine Market, By Route of Administration:

• Oral
• Parenteral
• Topical

• Veterinary Orthopedic Medicine Market, By End Use:

• Veterinary Hospitals and Clinics
• Homecare Settings
• Others

• Veterinary Orthopedic Medicine Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE